NEW YORK (GenomeWeb) - Veracyte announced after the close of the market Thursday a 25 percent rise in third quarter revenues amid increased demand for the company's Afirma gene expression classifier (GEC) test.

For the three-month period ended Sept. 30, Veracyte's revenues increased to $12.3 million from $9.8 million in the year ago period, but missed analysts' consensus estimate of $12.7 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.